The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
Abstract Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors....
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Hereditary Cancer in Clinical Practice |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13053-017-0076-7 |